CG10504 antikoerper, CT29478 antikoerper, DmILK antikoerper, Dmel\\CG10504 antikoerper, ILK antikoerper, ilk antikoerper, l(3)78Ca antikoerper, p59 antikoerper, AA511515 antikoerper, ESTM24 antikoerper, zgc:65842 antikoerper, ILK-1 antikoerper, ILK-2 antikoerper, P59 antikoerper, p59ILK antikoerper, Integrin linked kinase antikoerper, integrin linked kinase antikoerper, integrin linked kinase S homeolog antikoerper, integrin-linked protein kinase antikoerper, integrin-linked kinase antikoerper, Ilk antikoerper, ILK antikoerper, ilk.S antikoerper, CpipJ_CPIJ016644 antikoerper, Bm1_20815 antikoerper, Tsp_07213 antikoerper, Tsp_07224 antikoerper, Tsp_15354 antikoerper, ilk antikoerper
Hintergrund
Transduction of extracellular matrix signals through integrins influences intracellular and extracellular functions, and appears to require interaction of integrin cytoplasmic domains with cellular proteins. Integrin-linked kinase (ILK) is an ankyrin repeat containing 51 kDa receptor-proximate serine-threonine kinase (1), with a reported migration rate of 59K. This 451 amino acid protein interacts with the cytoplasmic domain of the beta-1 integrin subunit and contains sequence motifs found in pleckstrin homology domains capable of interacting with phosphoinositide lipids. ILK is an upstream regulator of Pi(3)K dependant activation of protein kinase B (PKB/AKT) and inhibition of glycogen synthase kinase 3 (GSK-3). ILK2 expression is associated with mediation of cell architecture, adhesion to integrin substrates and anchorage-dependent growth in epithelial cells. ILK2 is overexpressed in some highly invasive tumor cell lines.